Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 19.10M | 21.11M | 21.69M | 21.82M | 22.30M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.61M | 35.27M | 37.84M | 38.26M | 42.04M |
Operating Income | -29.61M | -35.27M | -37.84M | -38.26M | -42.04M |
Income Before Tax | -31.56M | -37.11M | -39.45M | -39.75M | -44.89M |
Income Tax Expenses | 9.00K | 9.00K | 8.00K | 7.00K | 0.00 |
Earnings from Continuing Operations | -31.57 | -37.12 | -39.46 | -39.76 | -44.89 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -31.57M | -37.12M | -39.46M | -39.76M | -44.89M |
EBIT | -29.61M | -35.27M | -37.84M | -38.26M | -42.04M |
EBITDA | -27.21M | -33.01M | -35.73M | -36.24M | -40.01M |
EPS Basic | -1.16 | -1.49 | -1.66 | -1.68 | -1.96 |
Normalized Basic EPS | -0.72 | -0.93 | -1.04 | -1.05 | -1.26 |
EPS Diluted | -1.16 | -1.49 | -1.66 | -1.68 | -1.96 |
Normalized Diluted EPS | -0.72 | -0.93 | -1.04 | -1.05 | -1.26 |
Average Basic Shares Outstanding | 117.28M | 102.48M | 94.86M | 94.45M | 90.39M |
Average Diluted Shares Outstanding | 117.28M | 102.48M | 94.86M | 94.45M | 90.39M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |